Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III in-life study of topical nitroglycerin gel (MQX-503) versus placebo for Raynaud's phenomenon
2005-004979-37Phase 3Completed
- Sponsor
- MediQuest Therapeutics
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Raynaud disease comparing MQX-503 topical gel with Matching placebo gel (2 arms). Primary endpoints: Primary efficacy endpoint and Safety endpoint. Started Sep 2006; status: completed.
02
Drugs
MQX-503
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2005-004979-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004979-37.